An Indian Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Post Marketing Surveillance Study of Fiasp to Evaluate Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice
Latest Information Update: 22 Mar 2024
At a glance
- Drugs Insulin aspart (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 21 Oct 2022 Status changed from recruiting to completed.
- 20 Apr 2022 Planned End Date changed from 20 Jan 2022 to 20 Jul 2022.
- 20 Apr 2022 Planned primary completion date changed from 20 Jan 2022 to 20 Jul 2022.